Literature DB >> 16294218

Mechanisms of therapy-related carcinogenesis.

James M Allan1, Lois B Travis.   

Abstract

Therapy-related cancers, defined as second primary cancers that arise as a consequence of chemotherapy and/or radiotherapy, are unusual in that they have a well-defined aetiology. Knowledge of the specific nature of the initiating exposure and exactly when it occurred has made it easier to identify crucial genetic events and to model these in vitro and in vivo. As such, the study of therapy-related cancers has led to the elucidation of discrete mechanisms of carcinogenesis, including DNA double-strand-break-induced gene translocation and genomic instability conferred by loss of DNA repair. Unsurprisingly, some of these mechanisms seem to operate in the development of sporadic cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294218     DOI: 10.1038/nrc1749

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  99 in total

1.  Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.

Authors:  Navneet S Majhail; Ruta Brazauskas; J Douglas Rizzo; Ronald M Sobecks; Zhiwei Wang; Mary M Horowitz; Brian Bolwell; John R Wingard; Gerard Socie
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.

Authors:  Dan Yang; Xiaorui Fu; Xudong Zhang; Wencai Li; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2015-09-15       Impact factor: 2.967

Review 3.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 4.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

Review 5.  Mutation-associated fusion cancer genes in solid tumors.

Authors:  Frederic J Kaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

6.  XRCC1 deficiency influences the cytotoxicity and the genomic instability induced by Me-lex, a specific inducer of N3-methyladenine.

Authors:  Debora Russo; Gilberto Fronza; Laura Ottaggio; Paola Monti; Chiara Perfumo; Alberto Inga; Prema Iyer; Barry Gold; Paola Menichini
Journal:  DNA Repair (Amst)       Date:  2010-05-14

Review 7.  Hitting the bull's eye: novel directed cancer therapy through helicase-targeted synthetic lethality.

Authors:  Monika Aggarwal; Robert M Brosh
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

8.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 9.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; John M Joslin; Thelma R Tennant; Shalini C Reshmi; David J Young; Angela Stoddart; Richard A Larson; Michelle M Le Beau
Journal:  Chem Biol Interact       Date:  2009-12-01       Impact factor: 5.192

Review 10.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.